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Introduction: Venous thrombus resolution may be regulated by an angiogenic process that involves the
surrounding vein wall. The aims of this study were to determine whether: (i) thrombosis stimulates
activation of the angiogenic transcription factor, hypoxia-inducible factor (HIF) 1α, and downstream
expression of growth factors in vein wall; and (ii) upregulation of HIF1α in vein wall leads to increased
growth factor expression and enhanced thrombus resolution.
Materials and methods: HIF1α, vascular endothelial growth factor (VEGF), and placental growth factor (PLGF)
were quantiﬁed in mouse inferior vena cava (IVC) at days 1, 3, 7, and 14 after thrombus formation (n=10-13
per group). An additional group of thrombosed mice were treated with the prolyl-hydroxylase domain (PHD)
inhibitor, L-mimosine (L-mim) or vehicle control. HIF1α, VEGF, and PLGF in IVC were measured at days 1 and
7; and vein recanalisation and thrombus resolution were measured at days 7 and 10 (n=6-7 per group).
Results: HIF1α was expressed in thrombosed IVC and its levels remained relatively constant throughout
natural resolution. The levels of VEGF in thrombosed IVC were elevated at days 1 (Pb0.0001) and 3 (Pb0.05);
and PLGF at days 1 (Pb0.0001), 3 (Pb0.0001), and 7 (Pb0.0001). Treatment with L-mim led to: increased
HIF1α (Pb0.05), VEGF (Pb0.005), and PLGF (Pb0.001) levels in the IVC; decreased thrombus size (Pb0.01);
and increased vein recanalisation (Pb0.001).
Conclusions: HIF1α levels in vein wall are not affected by thrombosis and it appears that the angiogenic drive
in the vein surrounding resolving thrombus is regulated independently of HIF1α. Stimulating HIF1α levels in
the vein wall leads to an increased angiogenic drive and promotes vein recanalisation and thrombus
resolution.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.Deep vein thrombosis (DVT) has an incidence of 1 in 500 per year
[1] and approximately 1 in 3 DVT patients develop post-thrombotic
syndrome (PTS) within 5 years of thrombosis [2]. PTS is expensive to
treat and symptoms include leg pain, swelling, and chronic ulceration
[3,4].
Venous thrombi resolve naturally by a slow process of organisation
[5]. Veins that recanalise more rapidly following DVT have reduced
incidence of outﬂow obstruction and valvular reﬂux, which is
associated with improved clinical outcome [6–8]. Anticoagulation
does not accelerate resolution or reduce the incidence of PTS, and
carries a risk of pathological bleeding. Alternative treatments that
accelerate thrombus resolution without haemorrhagic side-effects
may arise from a better understanding of themechanisms that control
natural resolution.GF, vascular endothelial growth
va; L-mim, L-mimosine.
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ries).
-NC-ND license.The formation of neovascular channels both within and around the
thrombus, together with thrombus contraction, leads to vein
recanalisation [9–11]. This neovascularisation may be driven by the
expression of potent angiogenic factors within the thrombus [12–14],
and increasing their levels in the thrombus enhances recanalisation
[14–17].
We have recently shown that newly-formed and resolving
thrombus is hypoxic compared with venous blood [18]. The
remodeling response that normally follows hypoxia is controlled
primarily by hypoxia-inducible factor 1 (HIF1), which is a hetero-
dimeric nuclear transcription factor composed of α and β subunits
[19]. HIF1β is constitutively expressed but HIF1α is regulated in an
oxygen-dependent manner [20]. Prolyl hydroxylase domain (PHD)
enzymes hydroxylate HIF1α under normoxia, which targets this
subunit for rapid degradation via the ubiquitin-proteosome pathway.
Under hypoxic conditions, however, PHD activity is compromised and
HIF1α translocates to the nucleus, where it forms the active HIF1
complex with HIF1β [21]. HIF1 binds to the hypoxia-responsive
element (HRE), causing transcriptional upregulation of its target
genes, such as vascular endothelial growth factor (VEGF) [22].
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with increased levels of angiogenic HIF1 targets in the naturally
resolving thrombus and preventingHIF1α degradation in the thrombus
enhances vein recanalisation, thrombus neovascularisation, and throm-
bus resolution [18]. Thrombus resolution is also regulated by interaction
with the vein wall to which it adheres, and an angiogenic response
within the wall may be a source of many of the channels that appear
within the thrombus [10]. The contribution of the vein wall to the
impetus for neovascularisation, in the context of HIF1 expression and
angiogenic target gene induction is, however, unknown. We hypothe-
sised that formation of occlusive thrombus causes a relative hypoxia in
the surrounding vein wall, leading to increased levels of HIF1α, which
upregulates the expression of angiogenic factors that promote vein
recanalisation and thrombus resolution. The aims of this study were to
determine whether: (i) HIF1α is induced in the vein wall following
thrombus induction; (ii) this is associatedwith an increased angiogenic
drive; and (iii) increased HIF1α levels in the vein wall enhances vein
recanalisation and thrombus resolution.
Materials and methods
Mouse model of venous thrombosis
All experiments were performed under the Animals (Scientiﬁc
Procedures) Act, 1986, and approved by the local ethics committee.
Experimental venous thrombi were induced in the inferior vena cava
(IVC) of 8 week old male BALB/C mice using a combination of blood
ﬂow restriction and endothelial disturbance as previously described
[9,23,24].
Localisation of HIF1α in IVC during natural thrombus resolution
Transverse parafﬁn-sections (5 μm) of 1 and 7 day old thrombosed
IVC (n=3) were immunostained for HIF1α (anti-HIF1α, Stratech,
UK) following antigen retrieval by pressure cooking sections in citrate
buffer (0.3% sodium citrate, pH 6). Primary antibody binding was
detected using biotinylated rabbit anti-rat (Dako, UK) and extravidin
horseradish peroxidase complex (HRP, Sigma, UK). Isotype-matched
IgG was used as a negative control. Peroxidase activity was visualised
using an HRP substrate (SG, Vector, UK), which showed positive
staining as dark blue/black, and sections were counter-stained using
nuclear fast red.
Measurement of HIF1α, VEGF, and PLGF expression in IVC during natural
thrombus resolution
Thrombosed mice were anaesthetised 1 day (n=13), 3 days
(n=10), 7 days (n=13), and 14 days (n=10) after thrombus
induction and a laparotomy was performed. IVC was immediately
separated from the thrombus, excised, snap frozen in liquid nitrogen,
and stored at −80 °C. The IVC from 13 sham operated mice was
harvested 24-hours post-operation to determine whether the pres-
ence of thrombus affects HIF1α, VEGF, and PLGF expression in the IVC.
The infrarenal aorta was also harvested from these mice and HIF1α
measured.
As HIF1β is constitutively expressed, the rate-limiting factor for HIF1
activation is accumulation and translocation of HIF1α to the nucleus.
Both the nuclear and cytoplasmic fractions of IVC samples were
therefore extracted using an extraction kit according to manufacturer's
instructions (NE-PER ExtractionKit, Pierce, UK) [25–27]. Soluble protein
concentrations in each fraction were measured using the Coomassie
Plus modiﬁed Bradford assay (Pierce, UK).
The levels of HIF1α in nuclear fractions (active HIF1α) were
measured using a human/mouse HIF1α ELISA (R&D Systems, UK). The
levels of VEGF and PLGF (potent angiogenic factors that have been
shown to be upregulated in hypoxic thrombus [18]) weremeasured incytoplasmic fractions using mouse VEGF and PLGF ELISAs (R&D
Systems, UK).
Effect of L-mimosine on HIF1α, VEGF, and PLGF expression in IVC
L-mimosine (L-mim) is a PHD inhibitor that has been used to
increase HIF1α levels in vitro and in vivo [28,29]. Thrombi were
formed in 34 mice and L-mim or vehicle control was administered as
previously described (n=17 per group) [18]. IVC was excised and
fractionated 1 day (n=10 per group) or 7 days (n=7 per group)
after thrombus induction. HIF1α expression was measured in nuclear
fractions; while VEGF and PLGF expression were measured in
cytoplasmic fractions. The concentrations of all factors were normal-
ized against the soluble protein concentration and expressed in
pg/mg.
Effect of L-mimosine on thrombus resolution
Thrombi were formed in 26 mice and L-mim or vehicle control was
administered as previously described (n=13 per group) [18]. The IVC
containing thrombus was harvested at day 7 (n=6 per group) or 10
(n=7 per group) after thrombus formation and ﬁxed in 10% formalin.
Transverse parafﬁn sections (5 μm) were taken at 300 μm intervals
along the entire length of the thrombus and stained with haematoxylin
and eosin. Images of whole tissue sections were obtained in a blinded
fashion using Image Pro Plus (Media Cybernetics, USA). Estimates of
thrombus size and IVC recanalisation (mm2) were obtained as
previously described [13,30].
Statistical analysis
TheKolmogorov-Smirnov testwasused to conﬁrm that all datawere
normally distributed. Unpaired t-tests were used to test differences in
HIF1α, VEGF, or PLGF between non-thrombosed and thrombosed IVC at
days 1, 3, 7, and 14 after thrombus formation. One-way analysis of
variance (ANOVA) was used to test whether there was a relationship
between time after thrombus induction and HIF1α, VEGF, or PLGF in
thrombosed IVC. If a relationship was present, Bonferroni's post-hoc
wasused to test differences betweengroups.Unpaired t-testswere used
to compare differences between L-mim-treated mice versus controls.
The relationships between HIF1α and VEGF or PLGF in the thrombosed
IVC of L-mim-treated mice were tested using Pearson's correlation.
P values of less than 0.05 were considered signiﬁcant. Data are
expressed as means ± standard error (SE).
Results
Localisation and measurement of HIF1α, VEGF, and PLGF in IVC during
natural thrombus resolution
Non-thrombosed IVC stained positively for HIF1α (Fig. 1A).
Thrombosed vein also stained positively for HIF1α at day 1 and 7
after thrombus induction (Fig. 1B).
The level of HIF1α in the non-thrombosed IVC wall (165±28 pg/mg)
was almost 2-fold greater than that found in the infrarenal aorta
(88±15 pg/mg, Pb0.05). There was however, no difference in HIF1α
expression between the non-thrombosed IVC (165±28 pg/mg) and
the thrombosed IVC at days 1 (162±17 pg/mg), 3 (111±21 pg/mg),
7 (111±15 pg/mg), or 14 (124±21 pg/mg) after thrombus formation
and there was no signiﬁcant temporal trend in HIF1α expression within
the wall (Fig. 2A).
There was a temporal pattern in both VEGF and PLGF expression in
the IVC following thrombus induction (Pb0.0001). VEGF expression in
thrombosed IVC was elevated at days 1 (130±20 pg/mg, Pb0.0001)
and 3 (53±9 pg/mg, P=0.01), but not 7 and 14 after thrombus
induction compared with the non-thrombosed IVC (28±4 pg/mg,
IgG control
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IVC
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Fig. 1. HIF1α staining of thrombosed IVC. Nucleated cells within the (A) non-thrombosed and (B) thrombosed (T) IVC stained positively for HIF1α (black).
348 C.E. Evans et al. / Thrombosis Research 128 (2011) 346–351Fig. 2B). VEGF in the thrombosed IVC was greater at day 1 compared
with days 3, 7, and 14 (Pb0.001 for all comparisons). PLGF in the
thrombosed IVC was raised at days 1 (104±12 pg/mg, Pb0.0001),
3 (115±14 pg/mg, Pb0.0001), and 7 (145±12 pg/mg, Pb0.0001), but
not at day 14 after thrombus induction compared with the non-
thrombosed IVC (26±4 pg/mg, Fig. 2C). PLGF in the thrombosed IVC
was increased at days 1 (Pb0.01), 3 (Pb0.01), and 7 (Pb0.001)
compared with day 14. There was no correlation between HIF1α andVEGF or PLGF in the non-thrombosed IVC or in the thrombosed IVC at
day 1, 3, 7, or 14 after thrombus formation.
The effect of L-mim on HIF1α, VEGF, and PLGF in IVC
HIF1α expression was 2-fold greater in both the day 1 and day 7
thrombosed IVC of mice treated with L-mim compared with controls
(Pb0.05, Table 1). HIF1α levels correlated positively with both VEGF
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Fig. 2. HIF1α, VEGF, and PLGF expression in thrombosed IVC. (A) HIF1α expression did
not change throughout thrombus resolution or when compared with the non-
thrombosed (NT) IVC. (B) VEGF was elevated at days 1 and 3 but not days 7 and 14,
compared with the non-thrombosed (NT) IVC and was greater at day 1 compared with
days 3, 7, and 14. (C) PLGF was higher at days 1, 3, and 7 after thrombus induction
compared with day 14 and the non-thrombosed (NT) IVC. *Pb0.01 vs. NT, day 7, and
day 14. **Pb0.0001 vs. NT and Pb0.01 vs. day 14. ***Pb0.0001 vs. NT and Pb0.001 vs.
days 3, 7, and 14.
Table 1
The effect of L-mim on HIF1α and HIF1-mediated angiogenic factor expression in
thrombosed IVC.
Values are pg/mg.
Vehicle control L-mimosine Signiﬁcance
Day 1 HIF1α 199±6 452±64 Pb0.05
VEGF 81±12 145±29 Pb0.05
PLGF 76±8 260±15 Pb0.0001
Day 7 HIF1α 80±8 126±14 Pb0.05
VEGF 24±4 51±8 Pb0.005
PLGF 80±9 87±10 PN0.5
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Fig. 3. Associations between HIF1α and VEGF or PLGF expression in the thrombosed IVC
of mice treated with L-mim. Positive correlations between HIF1α and (A) VEGF (n=17,
R=0.75, Pb0.001) or (B) PLGF (n=17, R=0.65, Pb0.01).
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Pb0.01, Fig. 3B) in the IVC wall of L-mim-treated mice, whereas there
were no signiﬁcant correlations between HIF1α and either VEGF or
PLGF in the IVC of control mice. VEGF expression was greater at day 1
(Pb0.05) and more than 2-fold greater at day 7 (Pb0.005, Table 1) in
the thrombosed IVC of mice treated with L-mim compared with
vehicle. PLGF expression was increased by over 3-fold at day 1
(PN0.0001, Table 1) in the thrombosed IVC of L-mim-treated mice
compared with controls.
The effect of L-mim treatment on thrombus resolution
Thrombus size was decreased in L-mim-treated mice compared
with controls at day 7 (1.0±0.2 versus 1.5±0.1 mm2, Pb0.01) andday 10 (0.8±0.1 versus 1.1±0.1 mm2, Pb0.05, Fig. 4A). Vein
recanalisation was increased by 2-fold at day 7 (0.1±0.02 versus
0.05±0.01 mm2, Pb0.05) and by almost 3-fold day 10 (0.27±0.03
versus 0.1±0.02 mm2, Pb0.001, Fig. 4B) in L-mim-treated mice
compared with controls.
Discussion
Organisation and resolution of venous thrombus involves an
angiogenic response from the vein wall that surrounds it [10]. We
have previously shown that a number of angiogenic factors are
temporally expressed within the resolving thrombus, including
HIF1α, PLGF [18], monocyte chemotactic protein (MCP) 1, ﬁbroblast
growth factor (FGF), and VEGF [12–14]. In this study we examined
whether: (i) presence of thrombus affects levels of HIF1α in vein wall;
(ii) this correlates with angiogenic drive; and (iii) increasing these
levels is associated with enhanced thrombus resolution and vein
recanalisation.
We have shown that the untreated IVC contains more active HIF1α
than both the thrombus that it surrounds (~12-fold increase) [18] and
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Fig. 4. Effect of L-mim treatment on thrombus resolution. Thrombus size (A) was
decreased in L-mim-treated mice compared with controls at day 7 and day 10, while
vein recanalisation (B) was increased at day 7 and day 10. *Pb0.05 vs. control. **Pb0.01
vs. control. ***Pb0.001 vs. control.
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effect on HIF1α level in the IVC, although both VEGF and PLGF exhibited
a temporal pattern of expression. Treatment with L-mim increased the
levels of HIF1α in the IVC and these levels correlated with an increased
angiogenic drive within the wall. The increased levels of HIF1α, VEGF,
and PLGF were also associated with enhanced vein recanalisation and
thrombus resolution. This led us to speculate that the effect of L-mim
treatment on vein recanalisation and thrombus resolution [18] may, at
least in part, be drivenbyHIF1-induced angiogenic geneexpression (e.g.
VEGF) in the IVC.
The similar levels of HIF1α in the IVC during natural thrombus
resolution and in non-thrombosed IVC suggests that oxygen tension
and HIF1α in the IVC is not affected by the presence of a thrombus or
the extent to which the thrombus has resolved. The mouse IVC is a
thin structure containing very few feeder microvessels (vena venora).
Oxygenation of the IVC is therefore likely to occur through diffusion of
oxygen from the blood in the vein lumen, which has a lower oxygen
tension than arterial blood. The high levels of active HIF1α in the IVC
may therefore be the result of chronic poor oxygenation.
The distinct temporal patterns of VEGF and PLGF and lack of
correlation with HIF1α in the IVC during thrombus resolution
suggests that VEGF and PLGF expression is HIF1-independent in the
IVC. Possible explanations for this may be that chronic exposure of the
IVC to a relatively hypoxic environment reduces the oxygen tension
threshold at which HIF1 activation leads to transcriptional upregula-
tion of its target genes in cells in this tissue. Expression of VEGF, for
example, can also be regulated by other transcription factors
including the transcriptional coactivator peroxisome-proliferator-
activated receptor-gamma coactivator 1 (PGC1), which is an oxygen
sensor that acts independently of HIF1 [20]. In the presence of
thrombus there is also an increased inﬂammatory cell inﬁltrate [31],
cells that could release a number of growth factors (including VEGFand PLGF) in an oxygen- and HIF1-independent manner. Treatment
with L-mim (that acts by an oxygen-independent mechanism)
resulted in increased HIF1α levels in the IVC and these levels were
positively correlated with both VEGF and PLGF expression.
VEGF is a potent angiogenic growth factor produced by endothelial
cells, macrophages, and neutrophils [32], which are present in the IVC
and inﬁltrate the thrombus during its resolution [10]. VEGF expression
has been localised to macrophages and endothelial cells at the
periphery of the resolving thrombus and surrounding the newly-
formed vascular channels within the thrombus [13]. Increasing VEGF
levels in the thrombus increased vein recanalisation and thrombus
resolution [16]. Enhancing the levels of angiogenic factors such as
VEGF could promote thrombus resolution and vein recanalisation in a
number ofways. These factors could increase: (i) local angiogenesis by
promoting the outgrowth of new vessels into the thrombus from the
vein wall; (ii) urokinase-type (uPA) and tissue-type plasminogen
activator (tPA) activity in endothelial cells, which increases local
ﬁbrinolysis [33]; (iii) survival or mobilization of endothelial cells or
their progenitors [34,35]; (iv) recruitment and activation of mono-
cytes and neutrophils [36]; and (v) activation of monocytes, expres-
sing proteolytic enzymes that remodel and organize the thrombus
[37]. PLGF expression in the IVC may promote vein recanalisation and
thrombus resolution by increasing; (i) growth,migration, and survival
of endothelial cells directly via VEGFR1 [38]; (ii) monocyte recruit-
ment; (iii) endothelial progenitor cell mobilisation [39]; and
(iv) expression of synergistically-acting angiogenic factors including
FGF, PDGF, and VEGF [40,41]. PLGF may also enhance VEGF signalling
by displacing it fromVEGFR1 and allowing it to bindwith VEGFR2 [42].
This study shows that the angiogenic drive derived from the vein
wall surrounding naturally-resolving thrombus is regulated indepen-
dently of HIF1α and provides data to support the notion that
increasing HIF1α levels in the environs of the thrombus promotes
an angiogenic milieu that drives resolution.Conﬂict of interest statement
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